Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1 ) Modulator Advanced into Clinical Trials

Journal of Medicinal Chemistry
John L GilmoreAlaric J Dyckman

Abstract

Recently, our research group reported the identification of BMS-986104 (2) as a differentiated S1P1 receptor modulator. In comparison to fingolimod (1), a full agonist of S1P1 currently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), 2 offers several potential advantages having demonstrated improved safety multiples in preclinical evaluations against undesired pulmonary and cardiovascular effects. In clinical trials, 2 was found to exhibit a pharmacokinetic half-life ( T1/2) longer than that of 1, as well as a reduced formation of the phosphate metabolite that is required for activity against S1P1. Herein, we describe our efforts to discover highly potent, partial agonists of S1P1 with a shorter T1/2 and increased in vivo phosphate metabolite formation. These efforts culminated in the discovery of BMS-986166 (14a), which was advanced to human clinical evaluation. The pharmacokinetic/pharmacodynamic (PK/PD) relationship as well as pulmonary and cardiovascular safety assessments are discussed. Furthermore, efficacy of 14a in multiple preclinical models of autoimmune diseases are presented.

References

Apr 23, 2002·The Journal of Biological Chemistry·Volker BrinkmannKevin R Lynch
Sep 18, 2003·The Journal of Biological Chemistry·Andreas BillichThomas Baumruker
Jul 7, 2005·Nature Reviews. Immunology·Hugh Rosen, Edward J Goetzl
Sep 15, 2006·The New England Journal of Medicine·Ludwig KapposUNKNOWN FTY720 D2201 Study Group
Sep 22, 2007·Analytical Biochemistry·Deanna L Siow, Binks W Wattenberg
Oct 30, 2007·Nature Neuroscience·Robert H Miller, Sha Mi
Nov 21, 2007·Nature Immunology·Susan R Schwab, Jason G Cyster
Aug 5, 2008·Biochimica Et Biophysica Acta·Timothy HlaJason Michaud
Sep 19, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jean E Merrill
Sep 15, 2009·American Journal of Respiratory Cell and Molecular Biology·Saad SammaniJoe G N Garcia
Jan 12, 2010·Clinical Neuropharmacology·Jerold Chun, Hans-Peter Hartung
Jan 19, 2010·American Journal of Respiratory Cell and Molecular Biology·Barry S SheaAndrew M Tager
May 11, 2011·The Journal of Clinical Investigation·Myat Lin OoTimothy Hla
Jun 18, 2011·International Journal of Clinical Practice·B SingerK Tobias
Jul 12, 2011·Critical Care Clinics·Nicolas Barnett, Lorraine B Ware
Dec 14, 2011·Clinical Pharmacokinetics·Olivier J DavidRobert L Schmouder
Dec 14, 2011·Annual Review of Immunology·Jason G Cyster, Susan R Schwab
Aug 1, 2012·British Journal of Pharmacology·Jaffar M KhanSian E Harding
Apr 2, 2013·Expert Opinion on Therapeutic Patents·Edward RobertsHugh Rosen
Dec 3, 2014·American Heart Journal·John CammVolker Brinkmann
Nov 25, 2016·MedChemComm·David MarcouxAlaric J Dyckman

❮ Previous
Next ❯

Citations

Feb 13, 2019·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Rui ZhaoDongping Tao
Apr 21, 2020·Expert Opinion on Investigational Drugs·Shalabh SinghalJohn Throup
Jan 13, 2021·Journal of Cellular Physiology·Federica CirilloLuigi Anastasia
Jan 26, 2022·Journal of Medicinal Chemistry·Sun Jun ParkKi Duk Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.